MedTrace Logo

Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients

NCT05490342 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2022-08-05

No results posted yet for this study

Summary

To investigate the variations in the humoral response to vaccines for the prevention of COVID-19 in liver transplant patients based on the type of immunosuppressive therapy adopted (tacrolimus based vs no-tacrolimus based) and immunosuppressive blood levels.

Conditions

  • SARS-CoV-2 Vaccination
  • Liver Transplantation

Interventions

DIAGNOSTIC_TEST

Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.

Blood test to value the antibody response to vaccination

Sponsors & Collaborators

  • University of Rome Tor Vergata

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05490342 on ClinicalTrials.gov